[Featured Stock] Helixmith Rises on Glass Lewis Voting Advisory

[Asia Economy Reporter Jang Hyowon] The stock price is showing strength following the announcement of the voting advisory report by Glass Lewis, one of the world's two major proxy advisory firms, on Helixmith's agenda for the extraordinary general meeting of shareholders.

As of 10:34 AM on the 5th, Helixmith is trading at 33,750 KRW, up 1.81% compared to the previous trading day.

On the 3rd, Glass Lewis released a report recommending investors to oppose the agenda items for the extraordinary general meeting of shareholders convened by the Helixmith minority shareholders' coalition.

Glass Lewis stated, "Although the current board members, including CEO Kim Sun-young and CEO Yoo Seung-shin, have faced difficulties due to the failure of the Phase 3 clinical trial of Enzygnis (VM202) for diabetic peripheral neuropathy (DPN), they have achieved progress in preparing several other clinical trials. While they should have proactively addressed the financial management issues that caused the rights offering, their recent responses are positive."

Additionally, Glass Lewis added that since the minority shareholders' coalition has not presented realistic alternatives for the company, they cannot support the appointment of directors recommended by the coalition.

The Helixmith minority shareholders' coalition has proposed agenda items for the extraordinary general meeting on the 14th, including amendments to the articles of incorporation and the appointment of six new directors to replace the current management team.

As Glass Lewis is the world's second-largest proxy advisory firm with over 1,000 institutional investors worldwide as clients, this report is expected to have a significant impact on Helixmith shareholders.

This content was produced with the assistance of AI translation services.